Trial reportWorld journal of urology2021
Detection of prostate cancer with
Trial report in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis.European radiology · 2024Pooled it
- The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study.Prostate cancer and prostatic diseases · 2026Trial
- Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy.Annals of surgical oncology · 2026Review
- Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer.Asian journal of urology · 2026Article
- The evolving role of positron emission tomography in precision prostate cancer biopsy.European journal of clinical investigation · 2025Review
- Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [European journal of nuclear medicine and molecular imaging · 2025Article
- Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study.BMC medical imaging · 2025Article
- Ultrasound super-resolution imaging for non-invasive assessment of microvessel in prostate lesion.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer.European journal of nuclear medicine and molecular imaging · 2024Article
- Diagnostic performance ofOncology letters · 2024Article
- Agreement between PSMA-RADS and E-PSMA systems in classifying [Frontiers in medicine · 2024Article
- The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer.European urology open science · 2024Article
- Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection.Theranostics · 2024Review
- A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies.European urology open science · 2023Article
- PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications.Diagnostics (Basel, Switzerland) · 2023Review
- The diagnostic performance ofFrontiers in oncology · 2023Article
- A Preclinical Study of anPharmaceuticals (Basel, Switzerland) · 2022Article
- The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn primary prostate cancer (PCa) patients, accurate staging and histologic grading are crucial to guide treatment decisions.
methodsThirty patients with intermediate-/high-risk primary PCa were prospectively enrolled between May 2018 and May 2019 and underwent
resultsThe segments recommended for potential targeted biopsy harboured csPCA in 28/30 patients (93%), and covered the highest Gleason score PCa segment in 26/30 patient (87%). Overall, 122 of 420 segments (29.0%) contained csPCa at final histopathological examination. Sensitivity, specificity, PPV and NPV for csPCa per segment using
conclusionsWhen comparing the PCa-localisation on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.